<DOC>
	<DOCNO>NCT01096784</DOCNO>
	<brief_summary>To compare severity retinopathy prematurity ( ROP ) among treated infant untreated control population , match gestational age birth confirm dose rhIGF-1/rhIGFBP-3 safe efficacious .</brief_summary>
	<brief_title>IGF-1/IGFBP3 Prevention Retinopathy Prematurity</brief_title>
	<detailed_description>When preterm infant deprive natural intrauterine environment lose access important factor , normally find utero , protein , growth factor , cytokine . It demonstrate insulin-like growth factor-1 ( IGF-1 ) one factor . In utero biological factor introduce fetus via placental absorption ingestion amniotic fluid . Deprivation factor likely cause inhibition improper stimulation important pathway , case eye may cause abnormal retinal vascular growth , hallmark retinopathy prematurity ( ROP ) . Retinopathy prematurity major cause blindness child develop develop world , despite availability current treatment late-stage ROP . As develop country provide neonatal maternal intensive care , increase survival preterm born infant , incidence ROP increase . This phase 2 study originally design 3 section , Sections A , B , C complete . The protocol amend patient enrol point forward enrol Section D. In Study Section D , total 120 subject ( GA 23 week + 0 day 27 week + 6 day ) randomly assign 1:1 allocation ratio either treatment rhIGF-1/rhIGFBP-3 receive standard neonatal care ( Control Group ) obtain least 80 evaluable subject . Duration infusion last long Study Day 0 ( day birth ) include PMA 29 week + 6 day , subject 's endogenous production IGF-1 consider sufficient maintain physiologic serum IGF-1 level . After discontinuation study drug infusion , subject follow PMA 40 week Â± 4 day .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<criteria>Signed informed consent parents/guardians ; Subject must GA 26 week + 0 day 27 week + 6 day ( Study Section A ) GA 23 week + 0 day 27 week + 6 day ( Study Sections B , C , D ) , inclusive Subjects bear small gestational age ( SGA ) , ie , body weight birth &lt; 2 standard deviation score ( SDS ) ( Study Section A ) Detectable gross malformation Known suspect chromosomal abnormality , genetic disorder , syndrome , accord Investigator 's opinion Persistent blood glucose level &lt; 2.5 mmol/L &gt; 10 mmol/L Study Day 0 ( day birth ) exclude severe congenital abnormality glucose metabolism Anticipated need administration erythropoietin ( rhEPO ) treatment study drug . Any maternal diabetes require insulin pregnancy Clinically significant neurological disease accord Investigator 's opinion ( Stage 1 IVH allow ) Any condition therapy , Investigator 's opinion , may pose risk subject interfere subject 's ability compliant protocol interfere interpretation result Monozygotic twin Subject participate plan participate clinical study another investigational study drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>insulin-like growth factor</keyword>
	<keyword>ROP</keyword>
	<keyword>IGF-I</keyword>
	<keyword>BPD</keyword>
	<keyword>bronchopulmonary dysplasia</keyword>
	<keyword>retinopathy prematurity</keyword>
</DOC>